-
Good News - Hybribio CYP2C9 and VKORC1 Gene MCA Real-time PCR Kit Obtained NMPA Registration Certificate
The CYP2C9 and VKORC1 Gene MCA Real-time PCR Kit (fluorescent PCR melting curve method) independently developed by Hybribio has officially obtained the registration certificate of Class III medical de
2024-01-18 古天乐代言太阳集团 105
-
Hybribio Unveils Comprehensive Cervical Cancer Screening and Diagnostic Solution at MEDICA 2023
The 55th International hospital and medical equipment exhibition, MEDICA 2023, was held in Düsseldorf, Germany from November 13th to 16th, 2023. Recognized as one of the world's largest medical B2
2023-11-18 古天乐代言太阳集团 261
-
Hybribio to Exhibit at MEDICA 2023
[Guangdong, 1 November 2023] Hybribio is excited to announce its participation in the upcoming MEDICA 2023 taking place in Düsseldorf, Germany from 13th November to 16th November. MEDICA, as one of th
2023-11-01 古天乐代言太阳集团 110
-
Meet Hybribio at TIF 2023
The 16th International Conference on Thalassaemia and Other Haemoglobinopathies & 18th TIF Conference for Patients and Parents will take place on 3-5 November 2023, at the Grand Hyatt Hotel, Kuala
2023-10-15 古天乐代言太阳集团 237
-
New Product Launch - ApoE and SLCO1B1 Gene MCA Real-time PCR Kit
Recently, Hybribio ApoE and SLCO1B1 Gene MCA Real-time PCR Kit (Fluorescence PCR melting curve method) has been approved by the National Medical Products Administration (NMPA) and obtained a Class III
2023-09-06 古天乐代言太阳集团 71
-
New Product Launch - Hybribio MTHFR Gene MCA Real-time PCR Kit Approved by NMPA
In August 17, 2023, Hybribio Biotech’s independently developed MTHFR Gene MCA Real-time PCR Kit (fluorescence PCR melting curve method) was officially awarded a Class III medical device registration c
2023-08-18 古天乐代言太阳集团 62